The polypill in the primary prevention of cardiovascular disease

Fundamental and Clinical Pharmacology

Volumn 24, Issue 1, 2010, Pages 29-35

  Wald, David S ^a   Wald, Nicholas J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Heart attack; Polypill; Primary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; PATIENT SELECTION; PILL; POLYPHARMACY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING TEST; STROKE; TABLET; TABLET FORMULATION;

AGE FACTORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DRUG COMBINATIONS; HUMANS; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; PATIENT SELECTION; PRIMARY PREVENTION; RISK FACTORS; STROKE;

EID: 74049133899     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00795.x     Document Type: Review

References (30)

1. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 326 1419 1423.
2. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (2003) 326 1427 1431.
3. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (2003) 326 1423 1427.
4. European patent specification: formulation for the prevention of cardiovascular disease. EP 1 272 220 B1. Proprietors Wald N.J., Law M.R.; priority 10.04.2000
5. The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 373 1341 1351.
6. Phase 2 study of heart polypill safety and efficacy in primary prevention of cardiovascuolar disease. http://clinicaltrials.gov/ct2/show/NCT00603590 DOI 15/6/2009.
7. Derry S., Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (2000) 321 1183 1187.
8. McQuaid K.R., Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. (2006) 119 624 638.
9. Antithromobotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 373 1821 1822.
10. MacMahon S., Peto R., Cutler J. et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 335 765 774.
11. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch. Intern. Med. (1992) 152 56 64.
12. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 360 1903 1913.
13. Wald D.S., Law M.R., Morris J. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ (2002) 325 1202 1206.
14. Wald N.J., Hackshaw A.K., Frost C.D. When can a risk factor be used as a worthwhile screening test? BMJ (1999) 319 1562 1565.
15. Wald N.J., Law M., Watt H. et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet (1994) 343 75 79.
16. Law M., Wald N.J., Morris J. Lowering blood pressure to prevent myocardial infarction and strokes: a new preventive strategy. Health Technol. Assess. (2003) 7 No 31.
17. Law M.R., Wald N.J., Wu T., Hackshaw A., Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ (1994) 308 363 366.
18. Law M., Morris J. The dose-response relationship between serum homocysteine and cardiovascular disease:implications for screening and treatment. Eur J Cardiovasc Prev Rehabil (2004) 11 250 253.
19. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults; collaborative analyses of 57 propsective studies. Lancet (2009) 373 1083 1096.
20. Khaw K.T., Wareham N., Luben R. et al. Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIV-Norfolk). BMJ (2001) 322 15.
21. D'Agostino R.B., Vasan R.S., Pencina M.J. et al. General cardiovascular risk profile for use in primary care. the Framingham heart study. Circulation (2008) 117 743 753.
22. De Backer G., Ambrosioni E., Borch-Johnsen K. et al. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts. Eur. Heart J. (2003) 24 1601 1610.
23. Hippisley-Cox J., Coupland C., Vinogradova Y. et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. A new cardiovascular disease risk score for the UK. BMJ (2008) 336 (7659) 1475 1482.
24. Department of Health. Putting prevention first. NHS Health Check: Vascular Risk Assessment and Management. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-097489.
25. 1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acuts myocardial infarction and 9805 controls. Eur. Heart J. (2009) 30) 2137 2146.
26. Wald D.S., Bestwick J.P. Carotid ultrasound screening for coronary heart disease: results based on a meta-analysis of 18 studies and 44,861 subjects. J. Med. Screen. (2009) 16 147 154.
27. Wald N.J., Morris J.K., Rish S. The efficacy of combining several risk factors as a screening test. J. Med. Screen. (2005) 12 197 201.
28. Office for National Statistics. Mortality Statistics Cause. 2003
29. Wald N., Law M. The Indian Polycap Study (TIPS). Lancet (2009) 374 781.
30. Yusuf S., Pais P., Xavier D. The Indian Polycap Study (TIPS): Authors' reply. La